Martin-Liberal J - Search Results

1

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.

Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Matos I, et al. Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9. Eur J Cancer. 2021. PMID: 34385069 Free article. Clinical Trial.

2

Prognostic score for patients with advanced melanoma treated with ipilimumab.

Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, Larkin J. Diem S, et al. Eur J Cancer. 2015 Dec;51(18):2785-91. doi: 10.1016/j.ejca.2015.09.007. Epub 2015 Nov 18. Eur J Cancer. 2015. PMID: 26597444

3

Immuno-Oncology: The Third Paradigm in Early Drug Development.

Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Martin-Liberal J, et al. Target Oncol. 2017 Apr;12(2):125-138. doi: 10.1007/s11523-016-0471-4. Target Oncol. 2017. PMID: 27995439

4

The expanding role of immunotherapy.

Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. Martin-Liberal J, et al. Cancer Treat Rev. 2017 Mar;54:74-86. doi: 10.1016/j.ctrv.2017.01.008. Epub 2017 Feb 11. Cancer Treat Rev. 2017. PMID: 28231560 Review.

5

Clinical research in small genomically stratified patient populations.

Martin-Liberal J, Rodon J. Martin-Liberal J, et al. Eur J Cancer. 2017 Jul;80:73-82. doi: 10.1016/j.ejca.2017.05.008. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591680 Review.

6

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Ochoa de Olza M, et al. Ann Oncol. 2018 Aug 1;29(8):1727-1740. doi: 10.1093/annonc/mdy225. Ann Oncol. 2018. PMID: 29945232 Free article. Review.

7

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E. Hierro C, et al. Clin Cancer Res. 2019 Jun 1;25(11):3210-3219. doi: 10.1158/1078-0432.CCR-18-3694. Epub 2019 Jan 22. Clin Cancer Res. 2019. PMID: 30670489 Review.

8

Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection.

Ros J, Matos I, Martin-Liberal J. Ros J, et al. Ann Oncol. 2019 Jul 1;30(7):1173-1177. doi: 10.1093/annonc/mdz129. Ann Oncol. 2019. PMID: 30977776 Free article. No abstract available.

9

Early-drug development in the era of immuno-oncology: are we ready to face the challenges?

Ochoa de Olza MO, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Ochoa de Olza MO, et al. Ann Oncol. 2019 Oct 1;30(10):1670. doi: 10.1093/annonc/mdz211. Ann Oncol. 2019. PMID: 31406973 Free article. No abstract available.

10

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.

Matos I, Martin-Liberal J, García-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Elez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodón J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Matos I, et al. Clin Cancer Res. 2020 Apr 15;26(8):1846-1855. doi: 10.1158/1078-0432.CCR-19-2226. Epub 2019 Nov 22. Clin Cancer Res. 2020. PMID: 31757877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page